Overview


According to FutureWise analysis the market for anti-inflammatory biologics is expected to reach US$ 229.22 billion by 2031 at a CAGR of 11.22%.

Anti-inflammatory biologics constitute a groundbreaking class of medications designed to address chronic inflammatory diseases with exceptional precision and effectiveness. These biologics are distinct from traditional pharmaceuticals, as they are derived from living organisms or produced through advanced biotechnological processes. What sets them apart is their ability to specifically target and modulate critical components of the immune system's inflammatory response, aiming to treat the root causes of diseases rather than merely alleviating symptoms. One of the most noteworthy characteristics of anti-inflammatory biologics is their specificity. These therapies are engineered to zero in on particular molecules, receptors, or pathways within the immune system that play pivotal roles in the inflammatory process. By selectively interfering with these immune responses, they can effectively curb excessive or misguided immune reactions, hallmark features of many inflammatory disorders. 

Anti-inflammatory biologics have demonstrated remarkable efficacy in managing a broad spectrum of conditions, including but not limited to rheumatoid arthritis, Crohn's disease, psoriasis, ankylosing spondylitis, and ulcerative colitis. For instance, tumor necrosis factor-alpha (TNF-alpha) inhibitors like adalimumab and infliximab are well-known anti-inflammatory biologics that block the action of TNF-alpha, a pro-inflammatory cytokine implicated in various autoimmune diseases. The method of administering these biologics varies and is determined by factors such as the specific drug, the condition being treated, individual patient responses, and preferences. Some anti-inflammatory biologics are delivered through subcutaneous injections, while others require intravenous infusion.

FutureWise Market Research has published a report that provides an insightful analysis of Anti-Inflammatory Biologics Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts’ projects that Anti-Inflammatory Biologics Market will experience a significant growth. According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  • AbbVie Inc.
  • Merck and Co., Inc.
  • Bristol-Myers Squibb Company
  • Johnson and Johnson Services, Inc.
  • Pfizer Inc.
  • Novartis AG
  • UCB S.A.
  • Eli Lilly and Company
  • Amgen Inc.
  • Biogen
  • AstraZeneca PLC
  • Roche
  • Sun Pharmaceutical Industries Ltd
  • Sanofi
  • GlaxoSmithKline

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent Development in Anti-Inflammatory Biologics Market:

  • In May 2023, AbbVie Inc. received approval for RINVOQ (upadacitinib) for treating adults with moderately to severely active Crohn's disease by the U.S. Food and Drug Administration (FDA). This product approval is expected to help the company enhance its product offerings in anti-inflammatory drugs and drive revenue progression.
  • In March 2022, Pfizer Inc acquired Arena Pharmaceuticals. This acquisition enables the company to develop and enhance its gastroenterology, dermatology, and cardiology product portfolio. This strategic acquisition helped the company complement its capabilities and expertise in the inflammation and immunology division.

The Anti-Inflammatory Biologics Market derives its momentum from a complex interplay of various driving factors. First and foremost, there is a noticeable surge in the prevalence of inflammatory diseases such as rheumatoid arthritis, Crohn's disease, psoriasis, and inflammatory bowel diseases. These chronic conditions afflict a substantial proportion of the global population, necessitating the utilization of biological therapies for effective disease management. This trend is further exacerbated by the aging demographic worldwide. As the international population ages, there is an inherent susceptibility to inflammatory diseases due to the natural aging process, resulting in an escalating demand for anti-inflammatory biologics. Moreover, the continuous evolution and innovation within the realm of biotechnology have played a pivotal role in propelling this market forward. Biologics, characterized by their precision and targeted therapeutic approach, have emerged as the preferred choice for managing these conditions. The ongoing refinement and development of biologics, marked by enhanced efficacy and safety profiles, contribute significantly to market expansion. Increasing awareness among both patients and healthcare professionals also plays a crucial role. Knowledge regarding the efficacy of biological therapies in managing inflammatory diseases has witnessed a substantial upsurge. As information about the benefits of these treatments spreads, acceptance and adoption rates have risen, bolstering market growth.

Several significant constraints affect the Anti-Inflammatory Biologics Market. One prominent limitation is the high cost associated with these therapies, often characterized by substantial price tags. This cost factor renders biologics inaccessible to a portion of patients and imposes strains on healthcare budgets, both at the individual and societal levels. Furthermore, safety concerns, although biologics are generally well-tolerated, persist as a restraint. These therapies can heighten susceptibility to infections and pose potential long-term risks, deterring both patients and healthcare providers and thus impacting market growth.
 

By Drug Class

  • Anti-Tumor Necrosis Factor (TNF)
  • Interleukin Antagonists
  • Janus Kinase (JAK) Inhibitors
  • Others

By Application

  • Rheumatoid Arthritis
  • Psoriasis
  • Others

By Route of Administration

  • Oral
  • Injection
    • Subcutaneous
    • Intravenous

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process. 

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. The North American anti-inflammatory drugs market held a substantial market share. This strong market position is primarily attributed to the rising prevalence of inflammatory conditions like rheumatoid arthritis, chronic obstructive pulmonary disease (COPD), and psoriasis, driving the industry's growth. Factors such as the increasing elderly population, sedentary lifestyles, and growing awareness of disease management are expected to fuel further the demand for anti-inflammatory medications in the North American region. The presence of advanced healthcare infrastructure, key industry players, and robust research and development capabilities have all played pivotal roles in driving the widespread adoption and commercial success of anti-inflammatory drugs in North America.

 

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Anti-Inflammatory Biologics Market By Drug Class, By Application, By Route of Administration, By Distribution Channel and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- Drug Class launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders

  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study

  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Global Anti-Inflammatory Biologics Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Anti-Inflammatory Biologics Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Global Anti-Inflammatory Biologics Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Global Anti-Inflammatory Biologics Market, By Drug Class Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Anti-Tumor Necrosis Factor (TNF)
        2. Interleukin Antagonists
        3. Janus Kinase (JAK) Inhibitors
        4. Others

  • 8.   Global Anti-Inflammatory Biologics Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Rheumatoid Arthritis
        2. Psoriasis
        3. Others

  • 9.   Global Anti-Inflammatory Biologics Market, By Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Oral
        2. Injection
         2.1. Subcutaneous
         2.2. Intravenous

  • 10.   Global Anti-Inflammatory Biologics Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospital Pharmacy
        2. Retail Pharmacy
        3. Online Pharmacy

  • 11.   North America Anti-Inflammatory Biologics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 12.   Latin America Anti-Inflammatory Biologics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 13.   Europe Anti-Inflammatory Biologics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 14.   Asia Pacific Anti-Inflammatory Biologics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 15.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 16.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 17.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Drug Classs Offered and Financial Layouts)
    •   1. AbbVie Inc.
         1.1. Company Overview
         1.2. Drug Class Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Merck and Co., Inc.
         2.1. Company Overview
         2.2. Drug Class Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Bristol-Myers Squibb Company
         3.1. Company Overview
         3.2. Drug Class Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Johnson and Johnson Services, Inc.
         4.1. Company Overview
         4.2. Drug Class Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Pfizer Inc.
         5.1. Company Overview
         5.2. Drug Class Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Novartis AG
         6.1. Company Overview
         6.2. Drug Class Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. UCB S.A.
         7.1. Company Overview
         7.2. Drug Class Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Eli Lilly and Company
         8.1. Company Overview
         8.2. Drug Class Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Amgen Inc.
         9.1. Company Overview
         9.2. Drug Class Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Biogen
         10.1.Company Overview
         10.2.Drug Class Portfolio
         10.3.SWOT Analysis
         10.4.Financial Overview
         10.5.Strategic Overview
        11. AstraZeneca PLC
         11.1.Company Overview
         11.2.Drug Class Portfolio
         11.3.SWOT Analysis
         11.4.Financial Overview
         11.5.Strategic Overview
        12. Roche
         12.1.Company Overview
         12.2.Drug Class Portfolio
         12.3.SWOT Analysis
         12.4.Financial Overview
         12.5.Strategic Overview
        13. Sun Pharmaceutical Industries Ltd
         13.1.Company Overview
         13.2.Drug Class Portfolio
         13.3.SWOT Analysis
         13.4.Financial Overview
         13.5.Strategic Overview
        14. Sanofi
         14.1.Company Overview
         14.2.Drug Class Portfolio
         14.3.SWOT Analysis
         14.4.Financial Overview
         14.5.Strategic Overview
        15. GlaxoSmithKline
         15.1.Company Overview
         15.2.Drug Class Portfolio
         15.3.SWOT Analysis
         15.4.Financial Overview
         15.5.Strategic Overview

  • 18.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 19.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients